[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f7v6KJHTAYgYxJ2As2l38enkqAXg2X3CL1hxVnd3F3-Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":84,"rows":91},"Technische Universität Dresden",[4],246,false,49,21,2022177,23,164,[14,17,19,21,24,26,28,31],{"name":15,"count":16},"Glaucoma",7,{"name":18,"count":16},"Acute Myeloid Leukemia",{"name":20,"count":16},"Alcoholism",{"name":22,"count":23},"Atopic Dermatitis",5,{"name":25,"count":23},"Healthy Subjects",{"name":27,"count":23},"Knee Osteoarthritis",{"name":29,"count":30},"Myelodysplastic Syndromes",4,{"name":32,"count":30},"Colorectal Cancer",[34,39,44,49,54,59,64,69,74,79],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT04089631","Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation","2023-06","Capecitabine",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06937788","Replication of the Heads Up Atopic Dermatitis Trial With Registry Data","2025-12-31","Upadacitinib",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04385290","Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","2027-04","MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05836896","A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","2027-06","MDC-CAR-BCMA001",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06701487","Role of Pavlovian Mechanisms for Control Over Substance Use","2027-06-30","fMRI imaging",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT05843877","Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula","2028-01","Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT05470595","A Single-arm Trial of Atezolizumab\u002FPlatinum\u002FEtoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung","2028-01-31","Atezolizumab",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT05904106","Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","2028-09","Venetoclax plus Azacitidine",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT07025824","Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation","2028-12","Treosulfan",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06696183","Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment","2029-04","Gilteritinib",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,117,139,197,230,255,273,291,309,327,351,369,387,414,435,453,471,496,518,543,570,588,609,627,683,705,727,753,778,804,829,854,878,905,923,949,967,985,1003,1028,1046,1071,1095,1119,1142,1187,1225,1256,1281,1299,1324,1350,1368,1393,1415,1440,1468,1486,1504,1522,1545,1569,1587,1605,1623,1641,1659,1707,1734,1771,1789,1807,1825,1843,1861,1879,1897,1921,1946,1969,1993,2017,2044,2062,2080,2103,2126,2144,2169,2193,2211,2235,2258,2276,2294,2312,2341,2372,2405,2436,2458,2482,2508,2533,2551,2573,2595,2620,2643,2667,2685,2703,2721,2743],{"intervention":63,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":113,"NA":115},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":93,"soonestReadout":62},[104],{"nctId":60,"briefTitle":61,"status":105,"phases":106,"primaryCompletion":62,"completion":62,"start":107,"enrollment":108,"conditions":109,"interventions":112},"RECRUITING",[88],"2025-01-28",32,[110,111],"Periampullary Cancer","Postoperative Pancreatic Fistula",[63],{"trials":114,"activeCount":97},[],{"trials":116,"activeCount":97},[],{"intervention":38,"totalTrials":93,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":135,"NA":137},{"trials":120,"activeCount":97},[],{"trials":122,"activeCount":97},[],{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":93,"soonestReadout":37},[127],{"nctId":35,"briefTitle":36,"status":105,"phases":128,"primaryCompletion":37,"completion":129,"start":130,"enrollment":131,"conditions":132,"interventions":134},[88],"2026-06","2020-06-26",4812,[133],"Colon Cancer Stage II",[38],{"trials":136,"activeCount":97},[],{"trials":138,"activeCount":97},[],{"intervention":140,"totalTrials":30,"cells":141},"Azacitidine",{"EARLY_PHASE1":142,"PHASE1":144,"PHASE2":157,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":143,"activeCount":97},[],{"trials":145,"activeCount":97},[146],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":151,"start":152,"conditions":153,"interventions":155},"NCT00923234","Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes","TERMINATED",[86],"2012-07","2009-06",[29,154],"Acute Myelogenous Leukemia",[140,156],"Lenalidomide",{"trials":158,"activeCount":93,"soonestReadout":82},[159,168,178],{"nctId":80,"briefTitle":81,"status":105,"phases":160,"primaryCompletion":82,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},[87],"2030-04","2025-04-25",60,[165],"AML - Acute Myeloid Leukemia",[83,167,140],"Venetoclax",{"nctId":169,"briefTitle":170,"status":149,"phases":171,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":175,"interventions":176},"NCT03769532","MRD-guided Treatment in NPM1mut AML Patients",[87],"2025-02-13","2019-08-21",26,[18],[177,140],"Pembrolizumab",{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":190},"NCT01462578","Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)","COMPLETED",[87],"2018-08","2021-02","2011-09",93,[188,189],"Acute Myelocytic Leukemia","Myelodysplastic Syndrome",[140],{"trials":192,"activeCount":97},[],{"trials":194,"activeCount":97},[],{"trials":196,"activeCount":97},[],{"intervention":167,"totalTrials":198,"cells":199},2,{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":201,"activeCount":97},[],{"trials":203,"activeCount":97},[],{"trials":205,"activeCount":93,"soonestReadout":82},[206,210],{"nctId":80,"briefTitle":81,"status":105,"phases":207,"primaryCompletion":82,"completion":161,"start":162,"enrollment":163,"conditions":208,"interventions":209},[87],[165],[83,167,140],{"nctId":211,"briefTitle":212,"status":213,"phases":214,"primaryCompletion":215,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},"NCT04330820","Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)","UNKNOWN",[86,87],"2023-10-11","2025-08","2020-04-06",55,[220,221],"Relapsed Adult AML","Refractory AML",[223],"Venetoclax Oral",{"trials":225,"activeCount":97},[],{"trials":227,"activeCount":97},[],{"trials":229,"activeCount":97},[],{"intervention":48,"totalTrials":93,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":249,"PHASE4":251,"NA":253},{"trials":233,"activeCount":97},[],{"trials":235,"activeCount":97},[],{"trials":237,"activeCount":93,"soonestReadout":47},[238],{"nctId":45,"briefTitle":46,"status":105,"phases":239,"primaryCompletion":47,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},[86,87],"2028-04","2020-09-04",214,[18],[48,245,246,247,248],"MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO","MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO","MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin","MAGMA-trial: conventional chemotherapy (AraC+DNR)+Midostaurin",{"trials":250,"activeCount":97},[],{"trials":252,"activeCount":97},[],{"trials":254,"activeCount":97},[],{"intervention":245,"totalTrials":93,"cells":256},{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":258,"activeCount":97},[],{"trials":260,"activeCount":97},[],{"trials":262,"activeCount":93,"soonestReadout":47},[263],{"nctId":45,"briefTitle":46,"status":105,"phases":264,"primaryCompletion":47,"completion":240,"start":241,"enrollment":242,"conditions":265,"interventions":266},[86,87],[18],[48,245,246,247,248],{"trials":268,"activeCount":97},[],{"trials":270,"activeCount":97},[],{"trials":272,"activeCount":97},[],{"intervention":246,"totalTrials":93,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":285,"PHASE4":287,"NA":289},{"trials":276,"activeCount":97},[],{"trials":278,"activeCount":97},[],{"trials":280,"activeCount":93,"soonestReadout":47},[281],{"nctId":45,"briefTitle":46,"status":105,"phases":282,"primaryCompletion":47,"completion":240,"start":241,"enrollment":242,"conditions":283,"interventions":284},[86,87],[18],[48,245,246,247,248],{"trials":286,"activeCount":97},[],{"trials":288,"activeCount":97},[],{"trials":290,"activeCount":97},[],{"intervention":247,"totalTrials":93,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":303,"PHASE4":305,"NA":307},{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":93,"soonestReadout":47},[299],{"nctId":45,"briefTitle":46,"status":105,"phases":300,"primaryCompletion":47,"completion":240,"start":241,"enrollment":242,"conditions":301,"interventions":302},[86,87],[18],[48,245,246,247,248],{"trials":304,"activeCount":97},[],{"trials":306,"activeCount":97},[],{"trials":308,"activeCount":97},[],{"intervention":248,"totalTrials":93,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":321,"PHASE4":323,"NA":325},{"trials":312,"activeCount":97},[],{"trials":314,"activeCount":97},[],{"trials":316,"activeCount":93,"soonestReadout":47},[317],{"nctId":45,"briefTitle":46,"status":105,"phases":318,"primaryCompletion":47,"completion":240,"start":241,"enrollment":242,"conditions":319,"interventions":320},[86,87],[18],[48,245,246,247,248],{"trials":322,"activeCount":97},[],{"trials":324,"activeCount":97},[],{"trials":326,"activeCount":97},[],{"intervention":78,"totalTrials":93,"cells":328},{"EARLY_PHASE1":329,"PHASE1":331,"PHASE2":333,"PHASE3":345,"PHASE4":347,"NA":349},{"trials":330,"activeCount":97},[],{"trials":332,"activeCount":97},[],{"trials":334,"activeCount":93,"soonestReadout":77},[335],{"nctId":75,"briefTitle":76,"status":336,"phases":337,"primaryCompletion":77,"completion":77,"start":338,"enrollment":339,"conditions":340,"interventions":342},"NOT_YET_RECRUITING",[87],"2025-09",220,[165,341],"MDS (Myelodysplastic Syndrome)",[78,343,344],"Melphalan","Fludarabine",{"trials":346,"activeCount":97},[],{"trials":348,"activeCount":97},[],{"trials":350,"activeCount":97},[],{"intervention":343,"totalTrials":93,"cells":352},{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":363,"PHASE4":365,"NA":367},{"trials":354,"activeCount":97},[],{"trials":356,"activeCount":97},[],{"trials":358,"activeCount":93,"soonestReadout":77},[359],{"nctId":75,"briefTitle":76,"status":336,"phases":360,"primaryCompletion":77,"completion":77,"start":338,"enrollment":339,"conditions":361,"interventions":362},[87],[165,341],[78,343,344],{"trials":364,"activeCount":97},[],{"trials":366,"activeCount":97},[],{"trials":368,"activeCount":97},[],{"intervention":344,"totalTrials":93,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":381,"PHASE4":383,"NA":385},{"trials":372,"activeCount":97},[],{"trials":374,"activeCount":97},[],{"trials":376,"activeCount":93,"soonestReadout":77},[377],{"nctId":75,"briefTitle":76,"status":336,"phases":378,"primaryCompletion":77,"completion":77,"start":338,"enrollment":339,"conditions":379,"interventions":380},[87],[165,341],[78,343,344],{"trials":382,"activeCount":97},[],{"trials":384,"activeCount":97},[],{"trials":386,"activeCount":97},[],{"intervention":388,"totalTrials":93,"cells":389},"Ivosidenib 250 MG",{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":391,"activeCount":97},[],{"trials":393,"activeCount":97},[],{"trials":395,"activeCount":93,"soonestReadout":400},[396],{"nctId":397,"briefTitle":398,"status":105,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":407},"NCT06717958","Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation",[87],"2029-10-01","2030-02-01","2025-06-17",76,[405,406],"AML","MDS",[388],{"trials":409,"activeCount":97},[],{"trials":411,"activeCount":97},[],{"trials":413,"activeCount":97},[],{"intervention":73,"totalTrials":93,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":429,"PHASE4":431,"NA":433},{"trials":417,"activeCount":97},[],{"trials":419,"activeCount":97},[],{"trials":421,"activeCount":93,"soonestReadout":72},[422],{"nctId":70,"briefTitle":71,"status":105,"phases":423,"primaryCompletion":72,"completion":72,"start":424,"enrollment":425,"conditions":426,"interventions":427},[87],"2024-04-07",146,[18],[73,428],"standard of care chemotherapy plus gemtuzumab ozogamicin",{"trials":430,"activeCount":97},[],{"trials":432,"activeCount":97},[],{"trials":434,"activeCount":97},[],{"intervention":428,"totalTrials":93,"cells":436},{"EARLY_PHASE1":437,"PHASE1":439,"PHASE2":441,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":438,"activeCount":97},[],{"trials":440,"activeCount":97},[],{"trials":442,"activeCount":93,"soonestReadout":72},[443],{"nctId":70,"briefTitle":71,"status":105,"phases":444,"primaryCompletion":72,"completion":72,"start":424,"enrollment":425,"conditions":445,"interventions":446},[87],[18],[73,428],{"trials":448,"activeCount":97},[],{"trials":450,"activeCount":97},[],{"trials":452,"activeCount":97},[],{"intervention":83,"totalTrials":93,"cells":454},{"EARLY_PHASE1":455,"PHASE1":457,"PHASE2":459,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":456,"activeCount":97},[],{"trials":458,"activeCount":97},[],{"trials":460,"activeCount":93,"soonestReadout":82},[461],{"nctId":80,"briefTitle":81,"status":105,"phases":462,"primaryCompletion":82,"completion":161,"start":162,"enrollment":163,"conditions":463,"interventions":464},[87],[165],[83,167,140],{"trials":466,"activeCount":97},[],{"trials":468,"activeCount":97},[],{"trials":470,"activeCount":97},[],{"intervention":472,"totalTrials":93,"cells":473},"Obrixtamig",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":490,"PHASE4":492,"NA":494},{"trials":475,"activeCount":97},[],{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":93,"soonestReadout":484},[480],{"nctId":481,"briefTitle":482,"status":336,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT07561645","A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung",[87],"2032-04","2026-07",75,[488],"Large Cell Neuroendocrine Carcinoma of the Lung",[472],{"trials":491,"activeCount":97},[],{"trials":493,"activeCount":97},[],{"trials":495,"activeCount":97},[],{"intervention":68,"totalTrials":93,"cells":497},{"EARLY_PHASE1":498,"PHASE1":500,"PHASE2":502,"PHASE3":512,"PHASE4":514,"NA":516},{"trials":499,"activeCount":97},[],{"trials":501,"activeCount":97},[],{"trials":503,"activeCount":93,"soonestReadout":67},[504],{"nctId":65,"briefTitle":66,"status":505,"phases":506,"primaryCompletion":67,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":511},"ACTIVE_NOT_RECRUITING",[87],"2029-01-31","2022-01-18",67,[488],[68],{"trials":513,"activeCount":97},[],{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":97},[],{"intervention":53,"totalTrials":93,"cells":519},{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":541},{"trials":521,"activeCount":97},[],{"trials":523,"activeCount":93,"soonestReadout":52},[524],{"nctId":50,"briefTitle":51,"status":105,"phases":525,"primaryCompletion":52,"completion":52,"start":526,"enrollment":527,"conditions":528,"interventions":534},[86],"2024-02-15",16,[529,530,531,532,533],"Neoplasms","Relapsed Diffuse Large B-cell Lymphoma (DLBCL)","Refractory Diffuse Large B-cell Lymphoma (DLBCL)","Multiple Myeloma, Refractory","Multiple Myeloma in Relapse",[53],{"trials":536,"activeCount":97},[],{"trials":538,"activeCount":97},[],{"trials":540,"activeCount":97},[],{"trials":542,"activeCount":97},[],{"intervention":58,"totalTrials":93,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":546,"activeCount":97},[],{"trials":548,"activeCount":97},[],{"trials":550,"activeCount":97},[],{"trials":552,"activeCount":97},[],{"trials":554,"activeCount":97},[],{"trials":556,"activeCount":93,"soonestReadout":57},[557],{"nctId":55,"briefTitle":56,"status":105,"phases":558,"primaryCompletion":57,"completion":57,"start":559,"enrollment":560,"conditions":561,"interventions":568},[],"2024-08-05",200,[562,20,563,564,565,566,567],"Alcohol Use Disorder (AUD)","Substance Use Disorders","Cannabis Use Disorder","Methamphetamine-dependence","Amphetamine Use Disorder","Cocaine Use Disorder",[58,569],"sMRI",{"intervention":569,"totalTrials":93,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":582},{"trials":573,"activeCount":97},[],{"trials":575,"activeCount":97},[],{"trials":577,"activeCount":97},[],{"trials":579,"activeCount":97},[],{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":93,"soonestReadout":57},[584],{"nctId":55,"briefTitle":56,"status":105,"phases":585,"primaryCompletion":57,"completion":57,"start":559,"enrollment":560,"conditions":586,"interventions":587},[],[562,20,563,564,565,566,567],[58,569],{"intervention":43,"totalTrials":93,"cells":589},{"EARLY_PHASE1":590,"PHASE1":592,"PHASE2":594,"PHASE3":596,"PHASE4":598,"NA":600},{"trials":591,"activeCount":97},[],{"trials":593,"activeCount":97},[],{"trials":595,"activeCount":97},[],{"trials":597,"activeCount":97},[],{"trials":599,"activeCount":97},[],{"trials":601,"activeCount":93,"soonestReadout":42},[602],{"nctId":40,"briefTitle":41,"status":105,"phases":603,"primaryCompletion":42,"completion":42,"start":604,"enrollment":605,"conditions":606,"interventions":607},[],"2021-08-02",240,[22],[43,608],"Dupilumab",{"intervention":608,"totalTrials":93,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":619,"NA":621},{"trials":612,"activeCount":97},[],{"trials":614,"activeCount":97},[],{"trials":616,"activeCount":97},[],{"trials":618,"activeCount":97},[],{"trials":620,"activeCount":97},[],{"trials":622,"activeCount":93,"soonestReadout":42},[623],{"nctId":40,"briefTitle":41,"status":105,"phases":624,"primaryCompletion":42,"completion":42,"start":604,"enrollment":605,"conditions":625,"interventions":626},[],[22],[43,608],{"intervention":628,"totalTrials":629,"cells":630},"Cytarabine",3,{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":646,"PHASE4":664,"NA":681},{"trials":632,"activeCount":97},[],{"trials":634,"activeCount":97},[],{"trials":636,"activeCount":97},[637],{"nctId":638,"briefTitle":639,"status":149,"phases":640,"primaryCompletion":641,"completion":641,"start":642,"enrollment":93,"conditions":643,"interventions":644},"NCT02229266","Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML",[87],"2017-04-22","2015-09",[18],[645,628],"NK cells",{"trials":647,"activeCount":97},[648],{"nctId":649,"briefTitle":650,"status":181,"phases":651,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":655,"interventions":657},"NCT02688140","Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia",[88],"2025-01-20","2016-06",133,[656],"Acute Promyelocytic Leukemia",[658,659,628,660,661,662,663],"Arsenic trioxide","Idarubicin","Tretinoin","Mitoxantrone","Mercaptopurine","Methotrexate",{"trials":665,"activeCount":97},[666],{"nctId":667,"briefTitle":668,"status":213,"phases":669,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":675},"NCT00180128","AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia",[89],"2012-11","2000-01",80,[674],"Leukemia, Promyelocytic, Acute",[676,677,678,679,680],"all-trans retinoid acid","idarubicin","mitoxantrone","daunorubicin","cytarabine",{"trials":682,"activeCount":97},[],{"intervention":677,"totalTrials":198,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":697,"NA":703},{"trials":686,"activeCount":97},[],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":97},[],{"trials":692,"activeCount":97},[693],{"nctId":649,"briefTitle":650,"status":181,"phases":694,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":695,"interventions":696},[88],[656],[658,659,628,660,661,662,663],{"trials":698,"activeCount":97},[699],{"nctId":667,"briefTitle":668,"status":213,"phases":700,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":701,"interventions":702},[89],[674],[676,677,678,679,680],{"trials":704,"activeCount":97},[],{"intervention":678,"totalTrials":198,"cells":706},{"EARLY_PHASE1":707,"PHASE1":709,"PHASE2":711,"PHASE3":713,"PHASE4":719,"NA":725},{"trials":708,"activeCount":97},[],{"trials":710,"activeCount":97},[],{"trials":712,"activeCount":97},[],{"trials":714,"activeCount":97},[715],{"nctId":649,"briefTitle":650,"status":181,"phases":716,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":717,"interventions":718},[88],[656],[658,659,628,660,661,662,663],{"trials":720,"activeCount":97},[721],{"nctId":667,"briefTitle":668,"status":213,"phases":722,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":723,"interventions":724},[89],[674],[676,677,678,679,680],{"trials":726,"activeCount":97},[],{"intervention":728,"totalTrials":93,"cells":729},"Ciclosporine A",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":751},{"trials":731,"activeCount":97},[],{"trials":733,"activeCount":97},[],{"trials":735,"activeCount":97},[],{"trials":737,"activeCount":97},[],{"trials":739,"activeCount":97},[740],{"nctId":741,"briefTitle":742,"status":181,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":749},"NCT00445081","Prednisolone vs. Ciclosporine in Severe Atopic Eczema",[89],"2009-09","2010-01","2007-03",66,[22],[750,728],"Prednisolone",{"trials":752,"activeCount":97},[],{"intervention":754,"totalTrials":93,"cells":755},"amine fluoride\u002Fstannous fluoride",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":776},{"trials":757,"activeCount":97},[],{"trials":759,"activeCount":97},[],{"trials":761,"activeCount":97},[],{"trials":763,"activeCount":97},[],{"trials":765,"activeCount":97},[766],{"nctId":767,"briefTitle":768,"status":181,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":775},"NCT01317446","Effect of Mouthrinsing on Inflammation of the Gums.",[89],"2012-01","2010-11",180,[774],"Gingivitis",[754],{"trials":777,"activeCount":97},[],{"intervention":779,"totalTrials":93,"cells":780},"Rasagiline",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":789,"NA":802},{"trials":782,"activeCount":97},[],{"trials":784,"activeCount":97},[],{"trials":786,"activeCount":97},[],{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[791],{"nctId":792,"briefTitle":793,"status":181,"phases":794,"primaryCompletion":795,"completion":642,"start":796,"enrollment":797,"conditions":798,"interventions":801},"NCT01442610","Effects of Rasagiline on Sleep Disturbances in Parkinson's Disease",[89],"2015-03","2011-10",30,[799,800],"Sleep Disturbances","Parkinsons's Disease",[779],{"trials":803,"activeCount":97},[],{"intervention":805,"totalTrials":93,"cells":806},"Azilect 1mg",{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":815,"NA":827},{"trials":808,"activeCount":97},[],{"trials":810,"activeCount":97},[],{"trials":812,"activeCount":97},[],{"trials":814,"activeCount":97},[],{"trials":816,"activeCount":97},[817],{"nctId":818,"briefTitle":819,"status":181,"phases":820,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":826},"NCT00902941","Olfaction in Patients With Parkinson's Disease Following Treatment With Rasagiline",[89],"2012-02","2009-05",34,[825],"Parkinson´s Disease",[805],{"trials":828,"activeCount":97},[],{"intervention":830,"totalTrials":93,"cells":831},"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone",{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":852},{"trials":833,"activeCount":97},[],{"trials":835,"activeCount":97},[],{"trials":837,"activeCount":97},[],{"trials":839,"activeCount":97},[],{"trials":841,"activeCount":97},[842],{"nctId":843,"briefTitle":844,"status":181,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT00180102","AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients \u003C= 60 Years",[89],"2009-11","2003-12",600,[850],"Leukemia, Nonlymphocytic, Acute",[830],{"trials":853,"activeCount":97},[],{"intervention":855,"totalTrials":93,"cells":856},"Elidel-Creme",{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":876},{"trials":858,"activeCount":97},[],{"trials":860,"activeCount":97},[],{"trials":862,"activeCount":97},[],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[867],{"nctId":868,"briefTitle":869,"status":181,"phases":870,"primaryCompletion":746,"completion":871,"start":872,"enrollment":873,"conditions":874,"interventions":875},"NCT00180141","Elidel-Study: Elidel in Patients With Atopic Dermatitis",[89],"2007-06","2005-04",24,[22],[855],{"trials":877,"activeCount":97},[],{"intervention":879,"totalTrials":93,"cells":880},"Cabergoline",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":903},{"trials":882,"activeCount":97},[],{"trials":884,"activeCount":97},[],{"trials":886,"activeCount":97},[],{"trials":888,"activeCount":97},[],{"trials":890,"activeCount":97},[891],{"nctId":892,"briefTitle":893,"status":181,"phases":894,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":901},"NCT00153972","Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease",[89],"2008-09","2009-01","2005-02",39,[900],"Parkinson's Disease",[879,902],"Levodopa",{"trials":904,"activeCount":97},[],{"intervention":902,"totalTrials":93,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":921},{"trials":908,"activeCount":97},[],{"trials":910,"activeCount":97},[],{"trials":912,"activeCount":97},[],{"trials":914,"activeCount":97},[],{"trials":916,"activeCount":97},[917],{"nctId":892,"briefTitle":893,"status":181,"phases":918,"primaryCompletion":895,"completion":896,"start":897,"enrollment":898,"conditions":919,"interventions":920},[89],[900],[879,902],{"trials":922,"activeCount":97},[],{"intervention":924,"totalTrials":93,"cells":925},"Midazolam",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":947},{"trials":927,"activeCount":97},[],{"trials":929,"activeCount":97},[],{"trials":931,"activeCount":97},[],{"trials":933,"activeCount":97},[],{"trials":935,"activeCount":97},[936],{"nctId":937,"briefTitle":938,"status":181,"phases":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":945},"NCT00188227","Comparison of Three Different Pain and Anxiety Reducing Methods in Adult Patients Undergoing Bone Marrow Puncture",[89],"2003-11","2001-09",748,[944],"Patients Undergoing Puncture of the Bone Marrow",[924,946],"Piritramid",{"trials":948,"activeCount":97},[],{"intervention":946,"totalTrials":93,"cells":950},{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":965},{"trials":952,"activeCount":97},[],{"trials":954,"activeCount":97},[],{"trials":956,"activeCount":97},[],{"trials":958,"activeCount":97},[],{"trials":960,"activeCount":97},[961],{"nctId":937,"briefTitle":938,"status":181,"phases":962,"completion":940,"start":941,"enrollment":942,"conditions":963,"interventions":964},[89],[944],[924,946],{"trials":966,"activeCount":97},[],{"intervention":676,"totalTrials":93,"cells":968},{"EARLY_PHASE1":969,"PHASE1":971,"PHASE2":973,"PHASE3":975,"PHASE4":977,"NA":983},{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[],{"trials":974,"activeCount":97},[],{"trials":976,"activeCount":97},[],{"trials":978,"activeCount":97},[979],{"nctId":667,"briefTitle":668,"status":213,"phases":980,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":981,"interventions":982},[89],[674],[676,677,678,679,680],{"trials":984,"activeCount":97},[],{"intervention":679,"totalTrials":93,"cells":986},{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":1001},{"trials":988,"activeCount":97},[],{"trials":990,"activeCount":97},[],{"trials":992,"activeCount":97},[],{"trials":994,"activeCount":97},[],{"trials":996,"activeCount":97},[997],{"nctId":667,"briefTitle":668,"status":213,"phases":998,"primaryCompletion":670,"completion":670,"start":671,"enrollment":672,"conditions":999,"interventions":1000},[89],[674],[676,677,678,679,680],{"trials":1002,"activeCount":97},[],{"intervention":1004,"totalTrials":93,"cells":1005},"Ciclosporin",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1026},{"trials":1007,"activeCount":97},[],{"trials":1009,"activeCount":97},[],{"trials":1011,"activeCount":97},[],{"trials":1013,"activeCount":97},[],{"trials":1015,"activeCount":97},[1016],{"nctId":1017,"briefTitle":1018,"status":149,"phases":1019,"primaryCompletion":1020,"completion":1021,"start":771,"enrollment":1022,"conditions":1023,"interventions":1024},"NCT01231854","Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.",[89],"2012-03","2013-03",15,[22],[1004,1025],"Alitretinoin",{"trials":1027,"activeCount":97},[],{"intervention":1025,"totalTrials":93,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1032,"PHASE2":1034,"PHASE3":1036,"PHASE4":1038,"NA":1044},{"trials":1031,"activeCount":97},[],{"trials":1033,"activeCount":97},[],{"trials":1035,"activeCount":97},[],{"trials":1037,"activeCount":97},[],{"trials":1039,"activeCount":97},[1040],{"nctId":1017,"briefTitle":1018,"status":149,"phases":1041,"primaryCompletion":1020,"completion":1021,"start":771,"enrollment":1022,"conditions":1042,"interventions":1043},[89],[22],[1004,1025],{"trials":1045,"activeCount":97},[],{"intervention":1047,"totalTrials":93,"cells":1048},"Cytarabine Dosage",{"EARLY_PHASE1":1049,"PHASE1":1051,"PHASE2":1053,"PHASE3":1055,"PHASE4":1057,"NA":1069},{"trials":1050,"activeCount":97},[],{"trials":1052,"activeCount":97},[],{"trials":1054,"activeCount":97},[],{"trials":1056,"activeCount":97},[],{"trials":1058,"activeCount":97},[1059],{"nctId":1060,"briefTitle":1061,"status":181,"phases":1062,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1068},"NCT00180115","AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients",[89],"2008-11","1996-02",400,[1067],"Leukemia, Nonlymphoblastic, Acute",[1047],{"trials":1070,"activeCount":97},[],{"intervention":1072,"totalTrials":93,"cells":1073},"Levetiracetam",{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1093},{"trials":1075,"activeCount":97},[],{"trials":1077,"activeCount":97},[],{"trials":1079,"activeCount":97},[],{"trials":1081,"activeCount":97},[],{"trials":1083,"activeCount":97},[1084],{"nctId":1085,"briefTitle":1086,"status":181,"phases":1087,"primaryCompletion":1088,"completion":1089,"start":1090,"enrollment":823,"conditions":1091,"interventions":1092},"NCT00307450","Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease",[89],"2009-03","2009-07","2006-03",[900],[1072],{"trials":1094,"activeCount":97},[],{"intervention":1096,"totalTrials":93,"cells":1097},"randomization between two established Chemotherapies",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1117},{"trials":1099,"activeCount":97},[],{"trials":1101,"activeCount":97},[],{"trials":1103,"activeCount":97},[],{"trials":1105,"activeCount":97},[],{"trials":1107,"activeCount":97},[1108],{"nctId":1109,"briefTitle":1110,"status":181,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1116},"NCT00180167","Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC",[89],"2010-07","2005-01",492,[850],[1096],{"trials":1118,"activeCount":97},[],{"intervention":1120,"totalTrials":93,"cells":1121},"Adapalen",{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1128,"PHASE4":1130,"NA":1140},{"trials":1123,"activeCount":97},[],{"trials":1125,"activeCount":97},[],{"trials":1127,"activeCount":97},[],{"trials":1129,"activeCount":97},[],{"trials":1131,"activeCount":97},[1132],{"nctId":1133,"briefTitle":1134,"status":213,"phases":1135,"primaryCompletion":152,"completion":744,"start":1136,"enrollment":163,"conditions":1137,"interventions":1139},"NCT00237978","Control of Therapy of Acne Papulopustulosa by Visible Light With Waterfiltered Infrared and \u002F or Adapalen (Differin Gel)",[89],"2006-09",[1138],"Acne Papulopustulosa",[1120],{"trials":1141,"activeCount":97},[],{"intervention":1143,"totalTrials":629,"cells":1144},"Budesonide",{"EARLY_PHASE1":1145,"PHASE1":1147,"PHASE2":1149,"PHASE3":1151,"PHASE4":1183,"NA":1185},{"trials":1146,"activeCount":97},[],{"trials":1148,"activeCount":97},[],{"trials":1150,"activeCount":97},[],{"trials":1152,"activeCount":97},[1153,1162,1172],{"nctId":1154,"briefTitle":1155,"status":181,"phases":1156,"primaryCompletion":746,"completion":1157,"start":1158,"enrollment":486,"conditions":1159,"interventions":1161},"NCT00180076","Budesonide for Maintenance Treatment of Collagenous Colitis",[88],"2008-03","2004-07",[1160],"Collagenous Colitis",[1143],{"nctId":1163,"briefTitle":1164,"status":181,"phases":1165,"primaryCompletion":1088,"completion":745,"start":1166,"enrollment":1167,"conditions":1168,"interventions":1171},"NCT00180089","Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation",[88],"2004-01",242,[1169,1170],"Leukemia","Graft-Versus-Host Disease",[1143],{"nctId":1173,"briefTitle":1174,"status":181,"phases":1175,"primaryCompletion":1176,"completion":1177,"start":1178,"enrollment":1179,"conditions":1180,"interventions":1182},"NCT00180050","Budesonide Treatment for Lymphocytic Colitis",[88],"2006-08","2007-08","2002-01",40,[1181],"Microscopic Colitis",[1143],{"trials":1184,"activeCount":97},[],{"trials":1186,"activeCount":97},[],{"intervention":1188,"totalTrials":198,"cells":1189},"Esomeprazole",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1221,"NA":1223},{"trials":1191,"activeCount":97},[],{"trials":1193,"activeCount":97},[],{"trials":1195,"activeCount":97},[],{"trials":1197,"activeCount":97},[1198,1207],{"nctId":1199,"briefTitle":1200,"status":213,"phases":1201,"completion":1202,"start":1203,"enrollment":1179,"conditions":1204,"interventions":1206},"NCT00455754","Esomeprazole Treatment for Patients With Lymphocytic Gastritis",[88],"2009-12","2007-02",[1205],"Lymphocytic Gastritis",[1188],{"nctId":1208,"briefTitle":1209,"status":213,"phases":1210,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1217},"NCT00455806","Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection",[88],"2008-02","2007-01",132,[1215,1216],"Helicobacter Pylori Infection","Chronic Gastritis",[1218,1219,1220],"esomeprazole","moxifloxacin","amoxicillin",{"trials":1222,"activeCount":97},[],{"trials":1224,"activeCount":97},[],{"intervention":1220,"totalTrials":198,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1252,"NA":1254},{"trials":1228,"activeCount":97},[],{"trials":1230,"activeCount":97},[],{"trials":1232,"activeCount":97},[],{"trials":1234,"activeCount":97},[1235,1248],{"nctId":1236,"briefTitle":1237,"status":213,"phases":1238,"completion":1239,"start":1240,"enrollment":560,"conditions":1241,"interventions":1244},"NCT00154440","Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation",[88],"2013-10","2001-11",[1242,1243],"Lymphoma","Lymphoma, Non-Hodgkin",[1245,1246,1220,1247],"proton pump inhibitor","clarithromycin","metronidazole",{"nctId":1208,"briefTitle":1209,"status":213,"phases":1249,"completion":1211,"start":1212,"enrollment":1213,"conditions":1250,"interventions":1251},[88],[1215,1216],[1218,1219,1220],{"trials":1253,"activeCount":97},[],{"trials":1255,"activeCount":97},[],{"intervention":1257,"totalTrials":93,"cells":1258},"Prophylactic platelet transfusion",{"EARLY_PHASE1":1259,"PHASE1":1261,"PHASE2":1263,"PHASE3":1265,"PHASE4":1277,"NA":1279},{"trials":1260,"activeCount":97},[],{"trials":1262,"activeCount":97},[],{"trials":1264,"activeCount":97},[],{"trials":1266,"activeCount":97},[1267],{"nctId":1268,"briefTitle":1269,"status":181,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1065,"conditions":1273,"interventions":1275},"NCT00521664","A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups",[88],"2010-09","2004-09",[1274],"Myeloid Leukemia",[1257,1276],"Therapeutic platelet transfusion",{"trials":1278,"activeCount":97},[],{"trials":1280,"activeCount":97},[],{"intervention":1276,"totalTrials":93,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1295,"NA":1297},{"trials":1284,"activeCount":97},[],{"trials":1286,"activeCount":97},[],{"trials":1288,"activeCount":97},[],{"trials":1290,"activeCount":97},[1291],{"nctId":1268,"briefTitle":1269,"status":181,"phases":1292,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":1065,"conditions":1293,"interventions":1294},[88],[1274],[1257,1276],{"trials":1296,"activeCount":97},[],{"trials":1298,"activeCount":97},[],{"intervention":1300,"totalTrials":93,"cells":1301},"Naltrexone",{"EARLY_PHASE1":1302,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1320,"NA":1322},{"trials":1303,"activeCount":97},[],{"trials":1305,"activeCount":97},[],{"trials":1307,"activeCount":97},[],{"trials":1309,"activeCount":97},[1310],{"nctId":1311,"briefTitle":1312,"status":181,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1319},"NCT02652585","Validation of a Test System for Development of Medications for Alcoholism",[88],"2017-08-25","2017-09-04","2016-02",46,[20],[1300],{"trials":1321,"activeCount":97},[],{"trials":1323,"activeCount":97},[],{"intervention":1325,"totalTrials":93,"cells":1326},"Acamprosate Calcium",{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1346,"NA":1348},{"trials":1328,"activeCount":97},[],{"trials":1330,"activeCount":97},[],{"trials":1332,"activeCount":97},[],{"trials":1334,"activeCount":97},[1335],{"nctId":1336,"briefTitle":1337,"status":181,"phases":1338,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1343,"interventions":1344},"NCT03634917","Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence",[88],"2023-08-30","2024-05-01","2020-08-05",82,[20],[1325,1345],"Calcium Carbonate",{"trials":1347,"activeCount":97},[],{"trials":1349,"activeCount":97},[],{"intervention":1345,"totalTrials":93,"cells":1351},{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1358,"PHASE4":1364,"NA":1366},{"trials":1353,"activeCount":97},[],{"trials":1355,"activeCount":97},[],{"trials":1357,"activeCount":97},[],{"trials":1359,"activeCount":97},[1360],{"nctId":1336,"briefTitle":1337,"status":181,"phases":1361,"primaryCompletion":1339,"completion":1340,"start":1341,"enrollment":1342,"conditions":1362,"interventions":1363},[88],[20],[1325,1345],{"trials":1365,"activeCount":97},[],{"trials":1367,"activeCount":97},[],{"intervention":1369,"totalTrials":93,"cells":1370},"Everolimus",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1375,"PHASE3":1377,"PHASE4":1389,"NA":1391},{"trials":1372,"activeCount":97},[],{"trials":1374,"activeCount":97},[],{"trials":1376,"activeCount":97},[],{"trials":1378,"activeCount":97},[1379],{"nctId":1380,"briefTitle":1381,"status":149,"phases":1382,"primaryCompletion":1383,"completion":1383,"start":1384,"enrollment":873,"conditions":1385,"interventions":1387},"NCT00117702","Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus",[87,88],"2008-05","2005-10",[1386],"Graft vs Host Disease",[1388,1369],"Tacrolimus",{"trials":1390,"activeCount":97},[],{"trials":1392,"activeCount":97},[],{"intervention":1394,"totalTrials":93,"cells":1395},"5-Azacytidin",{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1400,"PHASE3":1402,"PHASE4":1411,"NA":1413},{"trials":1397,"activeCount":97},[],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[],{"trials":1403,"activeCount":97},[1404],{"nctId":1405,"briefTitle":1406,"status":181,"phases":1407,"primaryCompletion":1202,"start":1212,"enrollment":1408,"conditions":1409,"interventions":1410},"NCT00422890","Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)",[88],10,[1274,189],[1394],{"trials":1412,"activeCount":97},[],{"trials":1414,"activeCount":97},[],{"intervention":1416,"totalTrials":93,"cells":1417},"study part 1 - dose daunorubicin",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1424,"PHASE4":1436,"NA":1438},{"trials":1419,"activeCount":97},[],{"trials":1421,"activeCount":97},[],{"trials":1423,"activeCount":97},[],{"trials":1425,"activeCount":97},[1426],{"nctId":1427,"briefTitle":1428,"status":181,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1432,"conditions":1433,"interventions":1435},"NCT02140242","Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML",[88],"2022-04-25","2014-04-16",721,[1434],"Leukemia, Myelocytic, Acute",[1416],{"trials":1437,"activeCount":97},[],{"trials":1439,"activeCount":97},[],{"intervention":1441,"totalTrials":93,"cells":1442},"Advagraf",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1464,"NA":1466},{"trials":1444,"activeCount":97},[],{"trials":1446,"activeCount":97},[],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[1451],{"nctId":1452,"briefTitle":1453,"status":213,"phases":1454,"primaryCompletion":1455,"completion":1456,"start":1457,"enrollment":1065,"conditions":1458,"interventions":1463},"NCT03672110","Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen",[88],"2020-02","2025-12","2014-09",[1459,1460,1461,1462],"Renal Failure","Renal Insufficiency","Renal Disease","Renal Insufficiency, Chronic",[1441],{"trials":1465,"activeCount":97},[],{"trials":1467,"activeCount":97},[],{"intervention":1245,"totalTrials":93,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":97},[],{"trials":1473,"activeCount":97},[],{"trials":1475,"activeCount":97},[],{"trials":1477,"activeCount":97},[1478],{"nctId":1236,"briefTitle":1237,"status":213,"phases":1479,"completion":1239,"start":1240,"enrollment":560,"conditions":1480,"interventions":1481},[88],[1242,1243],[1245,1246,1220,1247],{"trials":1483,"activeCount":97},[],{"trials":1485,"activeCount":97},[],{"intervention":1246,"totalTrials":93,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1500,"NA":1502},{"trials":1489,"activeCount":97},[],{"trials":1491,"activeCount":97},[],{"trials":1493,"activeCount":97},[],{"trials":1495,"activeCount":97},[1496],{"nctId":1236,"briefTitle":1237,"status":213,"phases":1497,"completion":1239,"start":1240,"enrollment":560,"conditions":1498,"interventions":1499},[88],[1242,1243],[1245,1246,1220,1247],{"trials":1501,"activeCount":97},[],{"trials":1503,"activeCount":97},[],{"intervention":1247,"totalTrials":93,"cells":1505},{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1518,"NA":1520},{"trials":1507,"activeCount":97},[],{"trials":1509,"activeCount":97},[],{"trials":1511,"activeCount":97},[],{"trials":1513,"activeCount":97},[1514],{"nctId":1236,"briefTitle":1237,"status":213,"phases":1515,"completion":1239,"start":1240,"enrollment":560,"conditions":1516,"interventions":1517},[88],[1242,1243],[1245,1246,1220,1247],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"intervention":1523,"totalTrials":93,"cells":1524},"Coenzyme Q10 Nanodispersion",{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1541,"NA":1543},{"trials":1526,"activeCount":97},[],{"trials":1528,"activeCount":97},[],{"trials":1530,"activeCount":97},[],{"trials":1532,"activeCount":97},[1533],{"nctId":1534,"briefTitle":1535,"status":181,"phases":1536,"primaryCompletion":1537,"completion":1537,"start":1538,"enrollment":1213,"conditions":1539,"interventions":1540},"NCT00180037","Coenzyme Q10 as a Symptomatic Treatment in Parkinson's Disease",[88],"2005-06","2003-09",[900],[1523],{"trials":1542,"activeCount":97},[],{"trials":1544,"activeCount":97},[],{"intervention":1546,"totalTrials":93,"cells":1547},"acarbose",{"EARLY_PHASE1":1548,"PHASE1":1550,"PHASE2":1552,"PHASE3":1554,"PHASE4":1565,"NA":1567},{"trials":1549,"activeCount":97},[],{"trials":1551,"activeCount":97},[],{"trials":1553,"activeCount":97},[],{"trials":1555,"activeCount":97},[1556],{"nctId":1557,"briefTitle":1558,"status":181,"phases":1559,"primaryCompletion":1560,"start":1561,"conditions":1562,"interventions":1564},"NCT00551954","Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes",[88],"2007-07","2006-07",[1563],"Type 2 Diabetes",[1546],{"trials":1566,"activeCount":97},[],{"trials":1568,"activeCount":97},[],{"intervention":658,"totalTrials":93,"cells":1570},{"EARLY_PHASE1":1571,"PHASE1":1573,"PHASE2":1575,"PHASE3":1577,"PHASE4":1583,"NA":1585},{"trials":1572,"activeCount":97},[],{"trials":1574,"activeCount":97},[],{"trials":1576,"activeCount":97},[],{"trials":1578,"activeCount":97},[1579],{"nctId":649,"briefTitle":650,"status":181,"phases":1580,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":1581,"interventions":1582},[88],[656],[658,659,628,660,661,662,663],{"trials":1584,"activeCount":97},[],{"trials":1586,"activeCount":97},[],{"intervention":660,"totalTrials":93,"cells":1588},{"EARLY_PHASE1":1589,"PHASE1":1591,"PHASE2":1593,"PHASE3":1595,"PHASE4":1601,"NA":1603},{"trials":1590,"activeCount":97},[],{"trials":1592,"activeCount":97},[],{"trials":1594,"activeCount":97},[],{"trials":1596,"activeCount":97},[1597],{"nctId":649,"briefTitle":650,"status":181,"phases":1598,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":1599,"interventions":1600},[88],[656],[658,659,628,660,661,662,663],{"trials":1602,"activeCount":97},[],{"trials":1604,"activeCount":97},[],{"intervention":662,"totalTrials":93,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1613,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[],{"trials":1612,"activeCount":97},[],{"trials":1614,"activeCount":97},[1615],{"nctId":649,"briefTitle":650,"status":181,"phases":1616,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":1617,"interventions":1618},[88],[656],[658,659,628,660,661,662,663],{"trials":1620,"activeCount":97},[],{"trials":1622,"activeCount":97},[],{"intervention":663,"totalTrials":93,"cells":1624},{"EARLY_PHASE1":1625,"PHASE1":1627,"PHASE2":1629,"PHASE3":1631,"PHASE4":1637,"NA":1639},{"trials":1626,"activeCount":97},[],{"trials":1628,"activeCount":97},[],{"trials":1630,"activeCount":97},[],{"trials":1632,"activeCount":97},[1633],{"nctId":649,"briefTitle":650,"status":181,"phases":1634,"primaryCompletion":652,"completion":652,"start":653,"enrollment":654,"conditions":1635,"interventions":1636},[88],[656],[658,659,628,660,661,662,663],{"trials":1638,"activeCount":97},[],{"trials":1640,"activeCount":97},[],{"intervention":1219,"totalTrials":93,"cells":1642},{"EARLY_PHASE1":1643,"PHASE1":1645,"PHASE2":1647,"PHASE3":1649,"PHASE4":1655,"NA":1657},{"trials":1644,"activeCount":97},[],{"trials":1646,"activeCount":97},[],{"trials":1648,"activeCount":97},[],{"trials":1650,"activeCount":97},[1651],{"nctId":1208,"briefTitle":1209,"status":213,"phases":1652,"completion":1211,"start":1212,"enrollment":1213,"conditions":1653,"interventions":1654},[88],[1215,1216],[1218,1219,1220],{"trials":1656,"activeCount":97},[],{"trials":1658,"activeCount":97},[],{"intervention":1660,"totalTrials":629,"cells":1661},"Cetuximab",{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1701,"PHASE4":1703,"NA":1705},{"trials":1663,"activeCount":97},[],{"trials":1665,"activeCount":97},[],{"trials":1667,"activeCount":97},[1668,1679,1693],{"nctId":1669,"briefTitle":1670,"status":181,"phases":1671,"primaryCompletion":1157,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},"NCT00153998","Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)",[87],"2004-11",135,[32,1675],"Liver Metastases",[1660,1677,1678],"Cetuximab and FOLFIRI","Cetuximab and FOLFOX",{"nctId":1680,"briefTitle":1681,"status":213,"phases":1682,"primaryCompletion":1683,"completion":1684,"start":1021,"enrollment":1685,"conditions":1686,"interventions":1687},"NCT01802645","Cetuximab\u002FFOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases",[87],"2019-09","2020-12",91,[32],[1660,1688,1689,1690,1691,1692],"Bevacizumab","Irinotecan","Oxaliplatin","5-FU","Folinic Acid",{"nctId":1694,"briefTitle":1695,"status":181,"phases":1696,"primaryCompletion":1697,"start":1212,"enrollment":9,"conditions":1698,"interventions":1700},"NCT00422773","Safety of Cetuximab and Oxaliplatin\u002F5-FU\u002FFA\u002FIrinotecan in First-Line Treatment of Metastatic Colorectal Cancer",[86,87],"2008-06",[1699],"Metastatic Colorectal Cancer",[1660],{"trials":1702,"activeCount":97},[],{"trials":1704,"activeCount":97},[],{"trials":1706,"activeCount":97},[],{"intervention":1708,"totalTrials":198,"cells":1709},"lenalidomide",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1718,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1711,"activeCount":97},[],{"trials":1713,"activeCount":97},[1714],{"nctId":147,"briefTitle":148,"status":149,"phases":1715,"primaryCompletion":151,"completion":151,"start":152,"conditions":1716,"interventions":1717},[86],[29,154],[140,156],{"trials":1719,"activeCount":97},[1720],{"nctId":1721,"briefTitle":1722,"status":149,"phases":1723,"primaryCompletion":1724,"completion":1724,"start":1725,"enrollment":1408,"conditions":1726,"interventions":1727},"NCT00720850","Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)",[87],"2011-01","2008-04",[29,154],[1708],{"trials":1729,"activeCount":97},[],{"trials":1731,"activeCount":97},[],{"trials":1733,"activeCount":97},[],{"intervention":1735,"totalTrials":198,"cells":1736},"pimecrolimus 1% cream",{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1753,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1738,"activeCount":97},[],{"trials":1740,"activeCount":97},[1741],{"nctId":1742,"briefTitle":1743,"status":181,"phases":1744,"primaryCompletion":1697,"completion":1745,"start":1746,"enrollment":1179,"conditions":1747,"interventions":1749},"NCT00655512","Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound",[86],"2008-10","2008-01",[1748],"Healthy",[1735,1750,1751,1752],"hydrocortisonacetat 1% cream","betamethasonvalerat 0,1% cream","clobetasol-17-propionat 0,05% cream",{"trials":1754,"activeCount":97},[1755],{"nctId":1756,"briefTitle":1757,"status":181,"phases":1758,"primaryCompletion":1759,"completion":896,"start":1760,"enrollment":1761,"conditions":1762,"interventions":1763},"NCT00610142","Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis",[87],"2008-08","2007-12",20,[22],[1735,1764],"hydrocortison 1% cream",{"trials":1766,"activeCount":97},[],{"trials":1768,"activeCount":97},[],{"trials":1770,"activeCount":97},[],{"intervention":1677,"totalTrials":93,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":97},[],{"trials":1776,"activeCount":97},[],{"trials":1778,"activeCount":97},[1779],{"nctId":1669,"briefTitle":1670,"status":181,"phases":1780,"primaryCompletion":1157,"start":1672,"enrollment":1673,"conditions":1781,"interventions":1782},[87],[32,1675],[1660,1677,1678],{"trials":1784,"activeCount":97},[],{"trials":1786,"activeCount":97},[],{"trials":1788,"activeCount":97},[],{"intervention":1678,"totalTrials":93,"cells":1790},{"EARLY_PHASE1":1791,"PHASE1":1793,"PHASE2":1795,"PHASE3":1801,"PHASE4":1803,"NA":1805},{"trials":1792,"activeCount":97},[],{"trials":1794,"activeCount":97},[],{"trials":1796,"activeCount":97},[1797],{"nctId":1669,"briefTitle":1670,"status":181,"phases":1798,"primaryCompletion":1157,"start":1672,"enrollment":1673,"conditions":1799,"interventions":1800},[87],[32,1675],[1660,1677,1678],{"trials":1802,"activeCount":97},[],{"trials":1804,"activeCount":97},[],{"trials":1806,"activeCount":97},[],{"intervention":1688,"totalTrials":93,"cells":1808},{"EARLY_PHASE1":1809,"PHASE1":1811,"PHASE2":1813,"PHASE3":1819,"PHASE4":1821,"NA":1823},{"trials":1810,"activeCount":97},[],{"trials":1812,"activeCount":97},[],{"trials":1814,"activeCount":97},[1815],{"nctId":1680,"briefTitle":1681,"status":213,"phases":1816,"primaryCompletion":1683,"completion":1684,"start":1021,"enrollment":1685,"conditions":1817,"interventions":1818},[87],[32],[1660,1688,1689,1690,1691,1692],{"trials":1820,"activeCount":97},[],{"trials":1822,"activeCount":97},[],{"trials":1824,"activeCount":97},[],{"intervention":1689,"totalTrials":93,"cells":1826},{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1828,"activeCount":97},[],{"trials":1830,"activeCount":97},[],{"trials":1832,"activeCount":97},[1833],{"nctId":1680,"briefTitle":1681,"status":213,"phases":1834,"primaryCompletion":1683,"completion":1684,"start":1021,"enrollment":1685,"conditions":1835,"interventions":1836},[87],[32],[1660,1688,1689,1690,1691,1692],{"trials":1838,"activeCount":97},[],{"trials":1840,"activeCount":97},[],{"trials":1842,"activeCount":97},[],{"intervention":1690,"totalTrials":93,"cells":1844},{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1846,"activeCount":97},[],{"trials":1848,"activeCount":97},[],{"trials":1850,"activeCount":97},[1851],{"nctId":1680,"briefTitle":1681,"status":213,"phases":1852,"primaryCompletion":1683,"completion":1684,"start":1021,"enrollment":1685,"conditions":1853,"interventions":1854},[87],[32],[1660,1688,1689,1690,1691,1692],{"trials":1856,"activeCount":97},[],{"trials":1858,"activeCount":97},[],{"trials":1860,"activeCount":97},[],{"intervention":1691,"totalTrials":93,"cells":1862},{"EARLY_PHASE1":1863,"PHASE1":1865,"PHASE2":1867,"PHASE3":1873,"PHASE4":1875,"NA":1877},{"trials":1864,"activeCount":97},[],{"trials":1866,"activeCount":97},[],{"trials":1868,"activeCount":97},[1869],{"nctId":1680,"briefTitle":1681,"status":213,"phases":1870,"primaryCompletion":1683,"completion":1684,"start":1021,"enrollment":1685,"conditions":1871,"interventions":1872},[87],[32],[1660,1688,1689,1690,1691,1692],{"trials":1874,"activeCount":97},[],{"trials":1876,"activeCount":97},[],{"trials":1878,"activeCount":97},[],{"intervention":1692,"totalTrials":93,"cells":1880},{"EARLY_PHASE1":1881,"PHASE1":1883,"PHASE2":1885,"PHASE3":1891,"PHASE4":1893,"NA":1895},{"trials":1882,"activeCount":97},[],{"trials":1884,"activeCount":97},[],{"trials":1886,"activeCount":97},[1887],{"nctId":1680,"briefTitle":1681,"status":213,"phases":1888,"primaryCompletion":1683,"completion":1684,"start":1021,"enrollment":1685,"conditions":1889,"interventions":1890},[87],[32],[1660,1688,1689,1690,1691,1692],{"trials":1892,"activeCount":97},[],{"trials":1894,"activeCount":97},[],{"trials":1896,"activeCount":97},[],{"intervention":1898,"totalTrials":93,"cells":1899},"Ketokonazol 2% cream",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1915,"PHASE4":1917,"NA":1919},{"trials":1901,"activeCount":97},[],{"trials":1903,"activeCount":97},[],{"trials":1905,"activeCount":97},[1906],{"nctId":1907,"briefTitle":1908,"status":213,"phases":1909,"primaryCompletion":1910,"completion":1202,"start":1157,"enrollment":1911,"conditions":1912,"interventions":1914},"NCT00678756","Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol)in Keratinocytes of Psoriatic Skin, Using Cytochrom-P(CYP)Inhibitor Ketokonazol",[87],"2009-10",12,[1913],"Psoriasis Vulgaris",[1898],{"trials":1916,"activeCount":97},[],{"trials":1918,"activeCount":97},[],{"trials":1920,"activeCount":97},[],{"intervention":1922,"totalTrials":93,"cells":1923},"Clofarabine",{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1925,"activeCount":97},[],{"trials":1927,"activeCount":97},[],{"trials":1929,"activeCount":97},[1930],{"nctId":1931,"briefTitle":1932,"status":181,"phases":1933,"primaryCompletion":1934,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1939},"NCT01295307","Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[87],"2013-09","2013-12","2011-03",86,[18],[1922],{"trials":1941,"activeCount":97},[],{"trials":1943,"activeCount":97},[],{"trials":1945,"activeCount":97},[],{"intervention":1947,"totalTrials":93,"cells":1948},"ivy leaves dry extract",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"trials":1954,"activeCount":97},[1955],{"nctId":1956,"briefTitle":1957,"status":213,"phases":1958,"primaryCompletion":1935,"completion":1935,"start":1959,"enrollment":797,"conditions":1960,"interventions":1962},"NCT01692041","Effect of an add-on Treatment With Ivy Leaves Dry Extract on Lung Function in Bronchial Asthma",[87],"2012-04",[1961],"Asthma",[1947],{"trials":1964,"activeCount":97},[],{"trials":1966,"activeCount":97},[],{"trials":1968,"activeCount":97},[],{"intervention":1970,"totalTrials":93,"cells":1971},"Temsirolimus",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1987,"PHASE4":1989,"NA":1991},{"trials":1973,"activeCount":97},[],{"trials":1975,"activeCount":97},[],{"trials":1977,"activeCount":97},[1978],{"nctId":1979,"briefTitle":1980,"status":149,"phases":1981,"primaryCompletion":1982,"completion":1983,"start":1984,"enrollment":1761,"conditions":1985,"interventions":1986},"NCT01111448","Temsirolimus in Myelodysplastic Syndrome (MDS)",[87],"2013-06","2014-06","2010-04",[189],[1970],{"trials":1988,"activeCount":97},[],{"trials":1990,"activeCount":97},[],{"trials":1992,"activeCount":97},[],{"intervention":1994,"totalTrials":93,"cells":1995},"Eltrombopag",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1997,"activeCount":97},[],{"trials":1999,"activeCount":97},[],{"trials":2001,"activeCount":97},[2002],{"nctId":2003,"briefTitle":2004,"status":149,"phases":2005,"primaryCompletion":2006,"completion":2007,"start":2008,"enrollment":1213,"conditions":2009,"interventions":2010},"NCT02446145","A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients",[87],"2020-12-26","2023-01-25","2015-05",[18],[1994],{"trials":2012,"activeCount":97},[],{"trials":2014,"activeCount":97},[],{"trials":2016,"activeCount":97},[],{"intervention":2018,"totalTrials":93,"cells":2019},"Vemurafenib",{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2021,"activeCount":97},[],{"trials":2023,"activeCount":97},[],{"trials":2025,"activeCount":97},[2026],{"nctId":2027,"briefTitle":2028,"status":149,"phases":2029,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":1761,"conditions":2032,"interventions":2036},"NCT03430947","Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases",[87],"2023-02-10","2018-07-01",[2033,2034,2035],"Malignant Melanoma Stage IV","BRAF V600 Mutation","Brain Metastases",[2018,2037],"Cobimetinib",{"trials":2039,"activeCount":97},[],{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"intervention":2037,"totalTrials":93,"cells":2045},{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2056,"PHASE4":2058,"NA":2060},{"trials":2047,"activeCount":97},[],{"trials":2049,"activeCount":97},[],{"trials":2051,"activeCount":97},[2052],{"nctId":2027,"briefTitle":2028,"status":149,"phases":2053,"primaryCompletion":2030,"completion":2030,"start":2031,"enrollment":1761,"conditions":2054,"interventions":2055},[87],[2033,2034,2035],[2018,2037],{"trials":2057,"activeCount":97},[],{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":97},[],{"intervention":645,"totalTrials":93,"cells":2063},{"EARLY_PHASE1":2064,"PHASE1":2066,"PHASE2":2068,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2065,"activeCount":97},[],{"trials":2067,"activeCount":97},[],{"trials":2069,"activeCount":97},[2070],{"nctId":638,"briefTitle":639,"status":149,"phases":2071,"primaryCompletion":641,"completion":641,"start":642,"enrollment":93,"conditions":2072,"interventions":2073},[87],[18],[645,628],{"trials":2075,"activeCount":97},[],{"trials":2077,"activeCount":97},[],{"trials":2079,"activeCount":97},[],{"intervention":2081,"totalTrials":93,"cells":2082},"Plerixafor",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2087,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[],{"trials":2088,"activeCount":97},[2089],{"nctId":2090,"briefTitle":2091,"status":181,"phases":2092,"primaryCompletion":2093,"completion":2093,"start":1935,"enrollment":898,"conditions":2094,"interventions":2096},"NCT01954914","Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers",[87],"2016-01",[2095],"Blood Stem Cell Harvest Failure",[2081],{"trials":2098,"activeCount":97},[],{"trials":2100,"activeCount":97},[],{"trials":2102,"activeCount":97},[],{"intervention":2104,"totalTrials":93,"cells":2105},"Ofatumumab",{"EARLY_PHASE1":2106,"PHASE1":2108,"PHASE2":2110,"PHASE3":2120,"PHASE4":2122,"NA":2124},{"trials":2107,"activeCount":97},[],{"trials":2109,"activeCount":97},[],{"trials":2111,"activeCount":97},[2112],{"nctId":2113,"briefTitle":2114,"status":181,"phases":2115,"primaryCompletion":2116,"completion":2116,"start":1021,"enrollment":1761,"conditions":2117,"interventions":2119},"NCT01809847","Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation",[87],"2015-01",[2118],"Chronic Lymphatic Leukemia",[2104],{"trials":2121,"activeCount":97},[],{"trials":2123,"activeCount":97},[],{"trials":2125,"activeCount":97},[],{"intervention":177,"totalTrials":93,"cells":2127},{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2132,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2129,"activeCount":97},[],{"trials":2131,"activeCount":97},[],{"trials":2133,"activeCount":97},[2134],{"nctId":169,"briefTitle":170,"status":149,"phases":2135,"primaryCompletion":172,"completion":172,"start":173,"enrollment":174,"conditions":2136,"interventions":2137},[87],[18],[177,140],{"trials":2139,"activeCount":97},[],{"trials":2141,"activeCount":97},[],{"trials":2143,"activeCount":97},[],{"intervention":2145,"totalTrials":93,"cells":2146},"Prospan Syrup",{"EARLY_PHASE1":2147,"PHASE1":2149,"PHASE2":2151,"PHASE3":2163,"PHASE4":2165,"NA":2167},{"trials":2148,"activeCount":97},[],{"trials":2150,"activeCount":97},[],{"trials":2152,"activeCount":97},[2153],{"nctId":2154,"briefTitle":2155,"status":213,"phases":2156,"primaryCompletion":2157,"completion":2157,"start":2158,"enrollment":163,"conditions":2159,"interventions":2162},"NCT02045550","Tolerance and Effect of a Prophylactical Treatment With Ivy Leaves Dry Extract in Recurrent Wheezy Bronchitis",[87],"2015-08","2014-01",[2160,2161],"Acute Wheezy Bronchitis","Recurrent Bronchitis",[2145],{"trials":2164,"activeCount":97},[],{"trials":2166,"activeCount":97},[],{"trials":2168,"activeCount":97},[],{"intervention":2170,"totalTrials":93,"cells":2171},"midostaurin",{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2173,"activeCount":97},[],{"trials":2175,"activeCount":97},[],{"trials":2177,"activeCount":97},[2178],{"nctId":2179,"briefTitle":2180,"status":181,"phases":2181,"primaryCompletion":2182,"completion":2182,"start":2183,"enrollment":2184,"conditions":2185,"interventions":2186},"NCT01830361","Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML",[87],"2019-10-30","2013-03-13",18,[18],[2170],{"trials":2188,"activeCount":97},[],{"trials":2190,"activeCount":97},[],{"trials":2192,"activeCount":97},[],{"intervention":1764,"totalTrials":93,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":97},[],{"trials":2198,"activeCount":97},[],{"trials":2200,"activeCount":97},[2201],{"nctId":1756,"briefTitle":1757,"status":181,"phases":2202,"primaryCompletion":1759,"completion":896,"start":1760,"enrollment":1761,"conditions":2203,"interventions":2204},[87],[22],[1735,1764],{"trials":2206,"activeCount":97},[],{"trials":2208,"activeCount":97},[],{"trials":2210,"activeCount":97},[],{"intervention":2212,"totalTrials":93,"cells":2213},"sorafenib",{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2215,"activeCount":97},[],{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[2220],{"nctId":2221,"briefTitle":2222,"status":181,"phases":2223,"primaryCompletion":2224,"completion":1457,"start":1088,"enrollment":2225,"conditions":2226,"interventions":2228},"NCT00893373","Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age",[87],"2011-11",276,[2227],"Acute Myeloid Leukemia (AML)",[2212],{"trials":2230,"activeCount":97},[],{"trials":2232,"activeCount":97},[],{"trials":2234,"activeCount":97},[],{"intervention":2236,"totalTrials":93,"cells":2237},"smart textiles containing menthol, camphor, cineol",{"EARLY_PHASE1":2238,"PHASE1":2240,"PHASE2":2250,"PHASE3":2252,"PHASE4":2254,"NA":2256},{"trials":2239,"activeCount":97},[],{"trials":2241,"activeCount":97},[2242],{"nctId":2243,"briefTitle":2244,"status":181,"phases":2245,"primaryCompletion":1176,"completion":1176,"start":1090,"enrollment":2246,"conditions":2247,"interventions":2249},"NCT00299559","Kinetics of Etheric Oils, Smart Textiles vs. Ointment",[86],6,[2248],"Common Cold",[2236],{"trials":2251,"activeCount":97},[],{"trials":2253,"activeCount":97},[],{"trials":2255,"activeCount":97},[],{"trials":2257,"activeCount":97},[],{"intervention":1750,"totalTrials":93,"cells":2259},{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2268,"PHASE3":2270,"PHASE4":2272,"NA":2274},{"trials":2261,"activeCount":97},[],{"trials":2263,"activeCount":97},[2264],{"nctId":1742,"briefTitle":1743,"status":181,"phases":2265,"primaryCompletion":1697,"completion":1745,"start":1746,"enrollment":1179,"conditions":2266,"interventions":2267},[86],[1748],[1735,1750,1751,1752],{"trials":2269,"activeCount":97},[],{"trials":2271,"activeCount":97},[],{"trials":2273,"activeCount":97},[],{"trials":2275,"activeCount":97},[],{"intervention":1751,"totalTrials":93,"cells":2277},{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2286,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2279,"activeCount":97},[],{"trials":2281,"activeCount":97},[2282],{"nctId":1742,"briefTitle":1743,"status":181,"phases":2283,"primaryCompletion":1697,"completion":1745,"start":1746,"enrollment":1179,"conditions":2284,"interventions":2285},[86],[1748],[1735,1750,1751,1752],{"trials":2287,"activeCount":97},[],{"trials":2289,"activeCount":97},[],{"trials":2291,"activeCount":97},[],{"trials":2293,"activeCount":97},[],{"intervention":1752,"totalTrials":93,"cells":2295},{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2304,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2297,"activeCount":97},[],{"trials":2299,"activeCount":97},[2300],{"nctId":1742,"briefTitle":1743,"status":181,"phases":2301,"primaryCompletion":1697,"completion":1745,"start":1746,"enrollment":1179,"conditions":2302,"interventions":2303},[86],[1748],[1735,1750,1751,1752],{"trials":2305,"activeCount":97},[],{"trials":2307,"activeCount":97},[],{"trials":2309,"activeCount":97},[],{"trials":2311,"activeCount":97},[],{"intervention":750,"totalTrials":198,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2322,"NA":2328},{"trials":2315,"activeCount":97},[],{"trials":2317,"activeCount":97},[],{"trials":2319,"activeCount":97},[],{"trials":2321,"activeCount":97},[],{"trials":2323,"activeCount":97},[2324],{"nctId":741,"briefTitle":742,"status":181,"phases":2325,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":2326,"interventions":2327},[89],[22],[750,728],{"trials":2329,"activeCount":97},[2330],{"nctId":2331,"briefTitle":2332,"status":181,"phases":2333,"primaryCompletion":1136,"completion":1157,"start":2334,"conditions":2335,"interventions":2337},"NCT00148746","Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis",[90],"2004-05",[2336],"Moderate to Severe Atopic Dermatitis",[2338,1388,750,2339,2340],"Pimecrolimus","Ciclosporin A","Dermatop",{"intervention":2342,"totalTrials":198,"cells":2343},"irbesartan",{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2350,"PHASE4":2352,"NA":2354},{"trials":2345,"activeCount":97},[],{"trials":2347,"activeCount":97},[],{"trials":2349,"activeCount":97},[],{"trials":2351,"activeCount":97},[],{"trials":2353,"activeCount":97},[],{"trials":2355,"activeCount":97},[2356,2363],{"nctId":2357,"briefTitle":2358,"status":181,"phases":2359,"completion":2360,"start":1178,"conditions":2361,"interventions":2362},"NCT00180024","Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.",[90],"2005-09",[25],[2342],{"nctId":2364,"briefTitle":2365,"status":181,"phases":2366,"completion":2367,"start":2368,"conditions":2369,"interventions":2370},"NCT00154024","Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.",[90],"2006-10","2003-03",[25],[2371,2342],"atorvastatin",{"intervention":2373,"totalTrials":198,"cells":2374},"rosiglitazone",{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2379,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2376,"activeCount":97},[],{"trials":2378,"activeCount":97},[],{"trials":2380,"activeCount":97},[],{"trials":2382,"activeCount":97},[],{"trials":2384,"activeCount":97},[],{"trials":2386,"activeCount":97},[2387,2394],{"nctId":2388,"briefTitle":2389,"status":181,"phases":2390,"completion":2391,"start":2360,"enrollment":873,"conditions":2392,"interventions":2393},"NCT00154011","Investigation of Vascular Relaxing Effects of the Antidiabetic Rosiglitazone.",[90],"2006-06",[25],[2373],{"nctId":2395,"briefTitle":2396,"status":181,"phases":2397,"primaryCompletion":2398,"completion":2399,"start":1176,"enrollment":2400,"conditions":2401,"interventions":2403},"NCT00324675","Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy",[90],"2008-12","2010-12",28,[1563,2402],"Overt Diabetic Nephropathy",[2404],"Rosiglitazone",{"intervention":2406,"totalTrials":198,"cells":2407},"pioglitazone",{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2414,"PHASE4":2425,"NA":2427},{"trials":2409,"activeCount":97},[],{"trials":2411,"activeCount":97},[],{"trials":2413,"activeCount":97},[],{"trials":2415,"activeCount":97},[2416],{"nctId":2417,"briefTitle":2418,"status":181,"phases":2419,"primaryCompletion":744,"completion":744,"start":1560,"conditions":2420,"interventions":2424},"NCT00507494","Influence of Pioglitazone for Renal Transplant Function in Diabetics",[88],[2421,2422,2423],"Diabetes Mellitus","Kidney Transplantation","Proteinuria",[2406],{"trials":2426,"activeCount":97},[],{"trials":2428,"activeCount":97},[2429],{"nctId":2430,"briefTitle":2431,"status":181,"phases":2432,"completion":1136,"start":1384,"enrollment":1179,"conditions":2433,"interventions":2434},"NCT00154037","Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.",[90],[25],[2435],"Pioglitazone",{"intervention":1388,"totalTrials":198,"cells":2437},{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2442,"PHASE3":2444,"PHASE4":2450,"NA":2452},{"trials":2439,"activeCount":97},[],{"trials":2441,"activeCount":97},[],{"trials":2443,"activeCount":97},[],{"trials":2445,"activeCount":97},[2446],{"nctId":1380,"briefTitle":1381,"status":149,"phases":2447,"primaryCompletion":1383,"completion":1383,"start":1384,"enrollment":873,"conditions":2448,"interventions":2449},[87,88],[1386],[1388,1369],{"trials":2451,"activeCount":97},[],{"trials":2453,"activeCount":97},[2454],{"nctId":2331,"briefTitle":2332,"status":181,"phases":2455,"primaryCompletion":1136,"completion":1157,"start":2334,"conditions":2456,"interventions":2457},[90],[2336],[2338,1388,750,2339,2340],{"intervention":2459,"totalTrials":93,"cells":2460},"bevacizumab treatment",{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2462,"activeCount":97},[],{"trials":2464,"activeCount":97},[],{"trials":2466,"activeCount":97},[],{"trials":2468,"activeCount":97},[],{"trials":2470,"activeCount":97},[],{"trials":2472,"activeCount":97},[2473],{"nctId":2474,"briefTitle":2475,"status":181,"phases":2476,"primaryCompletion":2398,"completion":2477,"start":2478,"enrollment":1761,"conditions":2479,"interventions":2481},"NCT00740168","Bevacizumab Treatment and Retinal Vessel Monitoring",[],"2009-04","2007-05",[2480],"Cancer",[2459],{"intervention":2483,"totalTrials":93,"cells":2484},"Lithium Carbonate",{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2486,"activeCount":97},[],{"trials":2488,"activeCount":97},[],{"trials":2490,"activeCount":97},[],{"trials":2492,"activeCount":97},[],{"trials":2494,"activeCount":97},[],{"trials":2496,"activeCount":97},[2497],{"nctId":2498,"briefTitle":2499,"status":213,"phases":2500,"primaryCompletion":2501,"completion":2502,"start":2158,"enrollment":2503,"conditions":2504,"interventions":2507},"NCT02039479","Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode",[90],"2018-03","2018-06",254,[2505,2506],"Suicidal Ideation\u002FBehavior","Depression",[2483],{"intervention":2509,"totalTrials":93,"cells":2510},"Biomarker analyses head & neck cancer tissue, blood specimen",{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2512,"activeCount":97},[],{"trials":2514,"activeCount":97},[],{"trials":2516,"activeCount":97},[],{"trials":2518,"activeCount":97},[],{"trials":2520,"activeCount":97},[],{"trials":2522,"activeCount":97},[2523],{"nctId":2524,"briefTitle":2525,"status":181,"phases":2526,"primaryCompletion":2527,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2532},"NCT02059668","Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)",[],"2022-06","2014-03",588,[2531],"Head and Neck Cancer",[2509],{"intervention":2371,"totalTrials":93,"cells":2534},{"EARLY_PHASE1":2535,"PHASE1":2537,"PHASE2":2539,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2536,"activeCount":97},[],{"trials":2538,"activeCount":97},[],{"trials":2540,"activeCount":97},[],{"trials":2542,"activeCount":97},[],{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[2547],{"nctId":2364,"briefTitle":2365,"status":181,"phases":2548,"completion":2367,"start":2368,"conditions":2549,"interventions":2550},[90],[25],[2371,2342],{"intervention":2552,"totalTrials":93,"cells":2553},"Ethanol",{"EARLY_PHASE1":2554,"PHASE1":2556,"PHASE2":2558,"PHASE3":2560,"PHASE4":2562,"NA":2564},{"trials":2555,"activeCount":97},[],{"trials":2557,"activeCount":97},[],{"trials":2559,"activeCount":97},[],{"trials":2561,"activeCount":97},[],{"trials":2563,"activeCount":97},[],{"trials":2565,"activeCount":97},[2566],{"nctId":2567,"briefTitle":2568,"status":181,"phases":2569,"primaryCompletion":1959,"completion":1959,"start":2399,"enrollment":2570,"conditions":2571,"interventions":2572},"NCT01097213","Neural Mechanisms Underlying Alcohol Induced Disinhibition",[],50,[20],[2552],{"intervention":2574,"totalTrials":93,"cells":2575},"Pentoxifylline retard 400mg",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2577,"activeCount":97},[],{"trials":2579,"activeCount":97},[],{"trials":2581,"activeCount":97},[],{"trials":2583,"activeCount":97},[],{"trials":2585,"activeCount":97},[],{"trials":2587,"activeCount":97},[2588],{"nctId":2589,"briefTitle":2590,"status":181,"phases":2591,"primaryCompletion":2093,"completion":2093,"start":846,"enrollment":16,"conditions":2592,"interventions":2594},"NCT00660868","Is Pentoxifylline Able to Improve Olfactory Sensitivity?",[],[2593],"Olfaction Disorders",[2574],{"intervention":2596,"totalTrials":93,"cells":2597},"Guanfacine",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2608},{"trials":2599,"activeCount":97},[],{"trials":2601,"activeCount":97},[],{"trials":2603,"activeCount":97},[],{"trials":2605,"activeCount":97},[],{"trials":2607,"activeCount":97},[],{"trials":2609,"activeCount":97},[2610],{"nctId":2611,"briefTitle":2612,"status":213,"phases":2613,"primaryCompletion":2614,"completion":2615,"start":2616,"enrollment":1179,"conditions":2617,"interventions":2619},"NCT04016207","Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin",[],"2021-03","2021-06","2020-04-01",[2618],"Affective Dysregulation",[2596],{"intervention":2621,"totalTrials":93,"cells":2622},"candesartan",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2633},{"trials":2624,"activeCount":97},[],{"trials":2626,"activeCount":97},[],{"trials":2628,"activeCount":97},[],{"trials":2630,"activeCount":97},[],{"trials":2632,"activeCount":97},[],{"trials":2634,"activeCount":97},[2635],{"nctId":2636,"briefTitle":2637,"status":181,"phases":2638,"completion":1561,"start":2334,"enrollment":2639,"conditions":2640,"interventions":2642},"NCT00154050","High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty",[90],22,[2641],"Arterial Occlusive Diseases",[2621],{"intervention":2644,"totalTrials":93,"cells":2645},"Povidone-Iodine",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2647,"activeCount":97},[],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[],{"trials":2653,"activeCount":97},[],{"trials":2655,"activeCount":97},[],{"trials":2657,"activeCount":97},[2658],{"nctId":2659,"briefTitle":2660,"status":181,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":672,"conditions":2664,"interventions":2666},"NCT02676791","Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection",[90],"2021-09-24","2016-02-16",[2665],"Esophageal Neoplasms",[2644],{"intervention":2338,"totalTrials":93,"cells":2668},{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2670,"activeCount":97},[],{"trials":2672,"activeCount":97},[],{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":97},[],{"trials":2678,"activeCount":97},[],{"trials":2680,"activeCount":97},[2681],{"nctId":2331,"briefTitle":2332,"status":181,"phases":2682,"primaryCompletion":1136,"completion":1157,"start":2334,"conditions":2683,"interventions":2684},[90],[2336],[2338,1388,750,2339,2340],{"intervention":2339,"totalTrials":93,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2695,"NA":2697},{"trials":2688,"activeCount":97},[],{"trials":2690,"activeCount":97},[],{"trials":2692,"activeCount":97},[],{"trials":2694,"activeCount":97},[],{"trials":2696,"activeCount":97},[],{"trials":2698,"activeCount":97},[2699],{"nctId":2331,"briefTitle":2332,"status":181,"phases":2700,"primaryCompletion":1136,"completion":1157,"start":2334,"conditions":2701,"interventions":2702},[90],[2336],[2338,1388,750,2339,2340],{"intervention":2340,"totalTrials":93,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2711,"PHASE4":2713,"NA":2715},{"trials":2706,"activeCount":97},[],{"trials":2708,"activeCount":97},[],{"trials":2710,"activeCount":97},[],{"trials":2712,"activeCount":97},[],{"trials":2714,"activeCount":97},[],{"trials":2716,"activeCount":97},[2717],{"nctId":2331,"briefTitle":2332,"status":181,"phases":2718,"primaryCompletion":1136,"completion":1157,"start":2334,"conditions":2719,"interventions":2720},[90],[2336],[2338,1388,750,2339,2340],{"intervention":2722,"totalTrials":93,"cells":2723},"L-NMMA",{"EARLY_PHASE1":2724,"PHASE1":2726,"PHASE2":2728,"PHASE3":2730,"PHASE4":2732,"NA":2734},{"trials":2725,"activeCount":97},[],{"trials":2727,"activeCount":97},[],{"trials":2729,"activeCount":97},[],{"trials":2731,"activeCount":97},[],{"trials":2733,"activeCount":97},[],{"trials":2735,"activeCount":97},[2736],{"nctId":2737,"briefTitle":2738,"status":181,"phases":2739,"completion":2360,"start":2740,"conditions":2741,"interventions":2742},"NCT00180063","Characterization of Local Vascular Effects of LNMMA",[90],"2003-10",[25],[2722],{"intervention":2744,"totalTrials":93,"cells":2745},"Protopic, Advantan",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2752,"PHASE4":2754,"NA":2756},{"trials":2747,"activeCount":97},[],{"trials":2749,"activeCount":97},[],{"trials":2751,"activeCount":97},[],{"trials":2753,"activeCount":97},[],{"trials":2755,"activeCount":97},[],{"trials":2757,"activeCount":97},[2758],{"nctId":2759,"briefTitle":2760,"status":181,"phases":2761,"primaryCompletion":2762,"completion":2763,"start":1272,"enrollment":2764,"conditions":2765,"interventions":2766},"NCT00236171","Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test",[90],"2006-04","2010-06",14,[1913],[2744]]